Yahoo · Aug 19, 2026
Atea (AVIR) Q2 2026 Earnings Call Transcript
HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients.
NASDAQ · AVIR
Atea Pharmaceuticals, Inc.
Healthcare · Biotechnology
$5.51
Down-$0.03 (-0.63%)
Updated Aug 27, 2026, 2:27 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 250M
- P/E ratio
- -1.97
- Dividend yield
- 0.00%
- 52-week range
- $2.78 – $6.45
- Volume
- 214.11K
- Avg. volume
- 399.61K
Price performance
AVIR price history
1M range · 0 trading sessions · Daily adjusted prices
AVIR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest AVIR news
The latest Smart Investors Daily articles mentioning AVIR.
Stock researchCompany · Overview
AVIR research
Overview
Company profile and research snapshot.
Company profile
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.88
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 9, 2026 | Evercore ISI Group | Outperform | — |
| Apr 11, 2025 | Morgan Stanley | Equal-Weight | — |
| Aug 13, 2024 | Morgan Stanley | Equal-Weight | — |
| Aug 10, 2023 | JP Morgan | Underweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
Yahoo · Aug 13, 2026
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Atea Pharmaceuticals, Inc.'s Q2 2026 earnings call
SeekingAlpha · Aug 12, 2026
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsJonae Barnes - Senior Vice President of Investor...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
